Pharma Mar (PHM.MC) Azione Prezzo
Pharma Mar Prezzo
Il fatturato è cresciuto a un tasso composto del 5,8% annuo negli ultimi 19 anni, raggiungendo 221,39 Mio. EUR. L'utile per azione è cresciuto del 21,2% all'anno negli ultimi 13 anni. Il margine netto di Pharma Mar si attesta al 33,9%, in calo rispetto al 40,4% di alcuni anni fa. Pharma Mar offre attualmente un rendimento da dividendo di circa il 1,19%. Il payout ratio è pari a circa il 18% degli utili. Il dividendo è cresciuto del 15,5% all'anno negli ultimi 18 anni. Gli analisti fissano un target di prezzo mediano di 107,10 EUR, ovvero il 58,7% sopra il prezzo attuale. Su 13 analisti, 9 valutano il titolo come acquisto — nel complesso un consenso Acquistare.
Pharma Mar Prezzo delle azioni
Accedi a questi dati tramite l’API Eulerpool
100.000 richieste/mese gratis · nessuna carta di credito
Pharma Mar Azione e analisi azionaria
Domande frequenti sull'azione Pharma Mar
The business model of Pharma Mar SA revolves around the research, development, and commercialization of innovative marine-derived pharmaceutical products. Pharma Mar specializes in the development of therapies derived from marine resources, particularly marine microorganisms. By harnessing the therapeutic potential of the sea, the company aims to bring effective treatments to patients suffering from various diseases, including cancer. With a focus on oncology, Pharma Mar seeks to address unmet medical needs and improve patients' lives globally. Through strategic partnerships, clinical trials, and ongoing research, Pharma Mar continues to drive advancements in the field of marine-derived pharmaceuticals.
Pharma Mar SA is primarily active in the pharmaceutical industry.
The main competitors of Pharma Mar SA in the market include other pharmaceutical companies operating in the same field and targeting similar market segments. Some notable competitors of Pharma Mar SA may include (examples only, not an exhaustive list): AstraZeneca, Novartis, Roche Holding, Pfizer, and Johnson & Johnson. These companies also focus on researching, developing, and marketing pharmaceutical products, including therapies and treatment options.
Pharma Mar SA is a leading biopharmaceutical company with a rich history and background. Established in 1986, the company is headquartered in Madrid, Spain. Pharma Mar SA focuses on the research, development, and commercialization of innovative marine-derived drugs to address various oncology and rare diseases. With a strong commitment to scientific excellence, Pharma Mar SA has built a diverse pipeline of potential therapies, leveraging the unique properties of marine organisms. The company has garnered global recognition for its breakthrough discovery of marine-derived compounds, including the development of Aplidin® (plitidepsin), a promising anticancer agent undergoing clinical trials. Pharma Mar SA continues to push boundaries in the pharmaceutical industry, striving to improve patients' lives worldwide.
Pharma Mar SA, a leading pharmaceutical company, has achieved significant milestones in its remarkable journey. The company's innovative approach and dedication to drug discovery have yielded remarkable results. Pharma Mar SA's milestones include successful clinical trials for their flagship drugs, receiving regulatory approvals, and securing strategic partnerships with renowned pharmaceutical companies. Furthermore, the company's consistent commitment to scientific research and development has resulted in groundbreaking discoveries that have revolutionized the treatment of various diseases. Through their remarkable achievements, Pharma Mar SA has solidified its position as a pioneering force in the pharmaceutical industry and continues to make invaluable contributions towards improving global healthcare.
Pharma Mar SA is primarily present in several countries and regions. The company has a strong presence in Spain, where it is based and operates its headquarters. Additionally, Pharma Mar SA has expanded its operations to various international markets, including the United States, Germany, Italy, France, and Switzerland. With a global presence, Pharma Mar SA strives to bring its innovative pharmaceutical products and treatments to patients worldwide.
Pharma Mar SA represents a set of core values and corporate philosophy that drive its operations. The company focuses on developing innovative therapies in the field of oncology and the treatment of other serious diseases. With a commitment to scientific excellence, Pharma Mar SA aims to create impactful solutions that improve patients' lives. Through strategic collaborations and continuous research, the company strives to deliver cutting-edge pharmaceutical products. Pharma Mar SA's dedication to ethical practices, transparency, and sustainability further reinforces its commitment to stakeholders and the global healthcare community.
Gli analisti fissano attualmente un prezzo obiettivo medio di 99,84 EUR per l’azione Pharma Mar (mediana: 107,10 EUR), pari a +47,9 % rispetto all’ultimo prezzo. Il consenso si basa su 13 giudizi di analisti.
13 analisti valutano attualmente l’azione Pharma Mar: 9 raccomandano l’acquisto, 3 la tenuta e 1 la vendita. Per il 2026 gli analisti si aspettano per Pharma Mar ricavi pari a 212,13 Mio. EUR e un utile per azione di 1,83 EUR.
L’azione Pharma Mar (PHM.MC) è quotata su 7 borse, tra cui: London (0RC6.L), Frankfurt (PMRA.F), München (PMRA.MU), Düsseldorf (PMRA.DU), Madrid (PHM.MC).
Pharma-Mar SA is a Spanish pharmaceutical company specializing in the development and marketing of cancer therapies. The company was founded in 1986 and is based in Colmenar Viejo, near Madrid. The company consists of two different business areas: Oncology and Consumer Healthcare. The Oncology division focuses on the development and marketing of innovative cancer drugs based on marine compounds, while the Consumer Healthcare division distributes over-the-counter drugs and cosmetic products. The company's business model is based on a strong research and development department that specializes in the exploration and development of cancer drugs based on marine compounds. They also collaborate with other pharmaceutical companies and research institutions to advance the research and development of cancer drugs. The company has a strong presence in international markets and has distribution partnerships in Europe, America, and Asia, allowing them to market their products worldwide and increase their revenue. Overall, Pharma-Mar SA is dedicated to the research, development, and distribution of cancer drugs, as well as over-the-counter drugs and cosmetic products.
Il attesa fatturato di Pharma Mar ammonta a 212,13 Mio. EUR. Questo dato si basa sui dati finanziari attuali e riflette lo sviluppo commerciale dell'azienda.
Il attesa profitto di Pharma Mar ammonta a 31,57 Mio. EUR. L'utile netto riflette la redditività dell'azienda dopo la deduzione di tutti i costi.
Il rapporto prezzo/utili (P/E) di Pharma Mar è attualmente 36,80. Il rapporto P/E confronta il prezzo attuale dell'azione con l'utile per azione e aiuta gli investitori a valutare la valutazione dell'azione Pharma Mar.
Il rapporto prezzo/fatturato (P/S) di Pharma Mar è attualmente 5,48. Il rapporto P/S confronta la capitalizzazione di mercato con il fatturato annuo e funge da indicatore di valutazione dell'azione Pharma Mar.
Il Quality Score AlleAktien per Pharma Mar è 3/10.
L'ISIN di Pharma Mar è ES0169501022. L'ISIN (International Securities Identification Number) è un codice identificativo univoco a livello mondiale per i titoli.
Il WKN di Pharma Mar è A2P9YT. Il WKN (Wertpapierkennnummer) è un codice identificativo tedesco a sei cifre per i titoli.
Il ticker di Pharma Mar è PHM.MC. Con questo simbolo di borsa vengono negoziate le azioni Pharma Mar in borsa.
Azione Pharma Mar
Gruppo di pari di Pharma Mar
Pharma Mar Ticker
Pharma Mar FIGI
Altre metriche e analisi di Pharma Mar in Deep Dive.
La nostra analisi azionaria dell'azione Pharma Mar include importanti indicatori finanziari come il fatturato, l'utile, il P/E, il P/S, l'EBIT, oltre a informazioni sul dividendo. Inoltre, esaminiamo aspetti come le azioni, la capitalizzazione di mercato, il debito, il patrimonio netto e le passività di Pharma Mar. Se state cercando informazioni più dettagliate su questi temi, sulle nostre sottopagine offriamo analisi approfondite: